Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation
| Autor: | Eric J. Topol, Jaap W. Deckers, James W. Box, Judith S. Hochman, David R. Holmes, Maarten L. Simoons, Robert M. Califf, Robert A. Harrington, David Hasdai, Alexander Battler |
|---|---|
| Přispěvatelé: | Cardiology |
| Rok vydání: | 2000 |
| Předmět: |
Blood Platelets
Male medicine.medical_specialty Time Factors Heart disease Coronary Disease Platelet Glycoprotein GPIIb-IIIa Complex Coronary Angiography Placebo Electrocardiography Double-Blind Method Internal medicine Myocardial Revascularization medicine Humans ST segment Myocardial infarction Aged Randomized Controlled Trials as Topic Retrospective Studies medicine.diagnostic_test Unstable angina business.industry Cardiogenic shock Shock Syndrome Middle Aged Prognosis medicine.disease Surgery Eptifibatide Cardiology Female Heart-Assist Devices business Cardiology and Cardiovascular Medicine medicine.drug |
| Zdroj: | Journal of the American College of Cardiology, 36(3), 685-692. Elsevier Inc. |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(00)00814-7 |
| Popis: | OBJECTIVESThe study examined whether antiplatelet treatment with eptifibatide affected the frequency and outcome of shock among patients in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial who had acute coronary syndromes but not persistent ST-segment elevation.BACKGROUNDPreliminary reports suggest a salutary effect of antiplatelet agents when shock complicates acute myocardial infarction.METHODSWe analyzed the impact of antiplatelet treatment with eptifibatide on the frequency and outcome of cardiogenic shock developing after enrollment. PURSUIT was a double-blind, randomized trial that examined the efficacy of eptifibatide (180 μg/kg bolus + continuous infusion of 2.0 μg/kg/min for ≤96 h) versus placebo among patients who had acute coronary syndromes but not persistent ST-segment elevation.RESULTSShock developed in 2.5% of the 9,449 patients at a median (25th, 75th interquartiles) of 94.0 (38, 206) h. Death by 30 days occurred in 65.8% of shock patients. Patients who had acute myocardial infarction upon enrollment had a greater incidence of shock (2.9% vs. 2.1%, p = 0.01), developed shock earlier (40.2% |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|